PRESS RELEASE published on 01/22/2025 at 07:00, 1 year 9 months ago Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US Relief Therapeutics completes strategic transition by selling GOLIKE rights outside the U.S. to Nutrisens, focusing on R&D and licensing for commercialized products. Company receives CHF 1.2 million upfront R&D Relief Therapeutics Licensing GOLIKE Nutrisens
BRIEF published on 12/27/2024 at 07:05, 1 year 10 months ago Relief Therapeutics Updates on Potential Merger with Renexxion Strategic Partnership Biopharmaceuticals Relief Therapeutics Renexxion Merger Gastrointestinal Therapies
BRIEF published on 12/27/2024 at 07:05, 1 year 10 months ago Relief Therapeutics fait le point sur une éventuelle fusion avec Renexxion Partenariat Stratégique Produits Biopharmaceutiques THÉRAPEUTIQUE DE SECOURS Fusion Renexxion Thérapies Gastro-intestinales
PRESS RELEASE published on 12/27/2024 at 07:00, 1 year 10 months ago Relief Therapeutics Provides Update on Potential Transaction with Renexxion Relief Therapeutics provides update on potential reverse merger with Renexxion, focusing on enhancing shareholder value and future growth opportunities in gastrointestinal disorders therapies Merger Biopharmaceutical Relief Therapeutics Clinical-stage Renexxion
BRIEF published on 12/16/2024 at 07:05, 1 year 10 months ago Relief Therapeutics Reports Promising Outcomes from PKU GOLIKE Trial Biopharmaceutical Clinical Trial PKU GOLIKE Phenylketonuria Metabolic Control
BRIEF published on 12/16/2024 at 07:05, 1 year 10 months ago Relief Therapeutics annonce des résultats prometteurs de l'essai GOLIKE sur la PKU Biopharmaceutique Essai Clinique PKU GOLIKE Phénylcétonurie Contrôle Métabolique
PRESS RELEASE published on 12/16/2024 at 07:00, 1 year 10 months ago Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial Relief Therapeutics announces final readout of PKU GOLIKE clinical trial showing superior metabolic control during prolonged fasting in PKU patients. Results aim to promote awareness and adoption of PKU GOLIKE Clinical Trial Relief Therapeutics PKU GOLIKE Phenylketonuria Metabolic Control
BRIEF published on 12/13/2024 at 23:05, 1 year 10 months ago Relief Therapeutics to End SEC Reporting Obligations with Form 15F Filing OTCQB SIX Swiss Exchange Relief Therapeutics SEC Reporting Form 15F
BRIEF published on 12/13/2024 at 23:05, 1 year 10 months ago Relief Therapeutics va mettre fin à ses obligations de déclaration auprès de la SEC avec le dépôt du formulaire 15F OTCQB Bourse Suisse SIX THÉRAPEUTIQUE DE SECOURS Formulaire 15F Rapports De La SEC
PRESS RELEASE published on 12/13/2024 at 23:00, 1 year 10 months ago Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations Relief Therapeutics announces filing of Form 15F to terminate SEC reporting obligations, maintaining listing on SIX Swiss Exchange and U.S. over-the-counter market SIX Swiss Exchange Relief Therapeutics SEC Reporting Form 15F U.S. OTCQB
Published on 11/10/2026 at 08:00, 25 minutes ago PEL 82 - QatarEnergy to Acquire 25% Participating Interest from Chevron
Published on 11/10/2026 at 02:45, 5 hours 40 minutes ago Presentation to Zurich Precious Metals Summit
Published on 11/09/2026 at 23:10, 9 hours 15 minutes ago Ur-Energy Reports Third Quarter 2026 Results
Published on 11/09/2026 at 23:00, 9 hours 25 minutes ago LNG Energy Group Announces Issuance of Third Partial Revocation Order and Proposed Shares-for-Debt Settlement
Published on 11/09/2026 at 22:32, 9 hours 53 minutes ago Announces Extension for Closing of Private Placement of Convertible Promissory Notes
Published on 11/10/2026 at 08:15, 9 minutes ago EOS Holding - Gen Z and millennials: tech-savvy, financially under pressure
Published on 11/10/2026 at 08:10, 14 minutes ago ANTHBOT Announces $250 / €250 Black Friday Discounts on M5 and M9 Robotic Lawn Mowers
Published on 11/10/2026 at 08:10, 14 minutes ago Quantinuum and RIKEN Expand Partnership to Accelerate the Commercialization of Quantum-AI Hybrid Supercomputing in Japan
Published on 11/10/2026 at 08:00, 25 minutes ago Capital Markets Day: HENSOLDT confirms revenue ambition of 6 billion euros for 2030 and aims for 10 billion euros in 2035
Published on 11/10/2026 at 07:00, 1 hour 25 minutes ago bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
Published on 11/10/2026 at 07:00, 1 hour 25 minutes ago bioMérieux obtient l’autorisation 510(k) de la FDA américaine et le marquage CE selon l’IVDR pour VITEK® PRO, son nouvel instrument automatisé d’identification et d’antibiogramme contribuant à la lutte contre l’antibiorésistance
Published on 11/09/2026 at 18:30, 13 hours 55 minutes ago Air Liquide has successfully issued a CHF 390 million multi-tranche bond
Published on 11/09/2026 at 18:30, 13 hours 55 minutes ago Air Liquide a réalisé avec succès une émission obligataire multi-tranches de 390 millions de CHF
